Nuvo Research Inc. is collaborating with Ferndale Laboratories, Inc. and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer (MMPE™) technology.

Under the terms of the collaboration agreement, Nuvo will utilize its proprietary MMPE technology to formulate two patented topical dermatology product candidates. Once the formulations are complete, Ferndale in collaboration with the CRO, will oversee and fund the formulations' advancement through Phase II clinical studies.  It is anticipated that the product candidates will then be made available for out-licensing. Licensing revenues, including upfront payments, milestone payments and royalties will be shared by the parties based on a formula that includes compensation to Nuvo for contributing the patented formulations.

This MMPE proprietary technology uses special combinations of molecular penetration enhancers to enhance delivery of a given drug into or through the skin. Nuvo holds U.S. patents that cover formulations utilizing certain combinations of particular molecular penetration enhancers (MPEs) together with active drugs in topical formulations. The company also holds a royalty-free license for devices useful in assessing MMPEs on the barrier properties of membranes (including human skin) which are covered by an issued U.S. patent.